Alkermes (ALKS) Change in Acquisitions & Divestments (2010 - 2026)
Alkermes' (ALKS) quarterly Change in Acquisitions & Divestments came in at $20.1 million in Q2 2026, down 75.38% year-over-year from $81.6 million in Q2 2025, and down 52.86% quarter-over-quarter from $42.6 million in Q1 2026.
Analysis
Alkermes (ALKS) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Change in Acquisitions & Divestments for 17 consecutive years, with $20.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Change in Acquisitions & Divestments fell 75.38% year-over-year to $20.1 million in Q2 2026; TTM through Jun 2026 was $565.1 million, a 54.23% increase from a year earlier, with the FY2025 full-year figure at $697.5 million, up 124.79% from the prior year.
- Change in Acquisitions & Divestments was $20.1 million for Q2 2026 at Alkermes, down from $42.6 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $377.1 million in Q4 2025 and troughed at $20.1 million in Q2 2026.
- A 5-year average of $94.9 million and a median of $82.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
- Across the five-year window, Change in Acquisitions & Divestments surged 341.06% in 2025 and tumbled 75.38% in 2026, its largest moves.
- Over 5 years, Change in Acquisitions & Divestments stood at $90.6 million in 2022, then slipped by 29.85% to $63.6 million in 2023, then jumped by 34.48% to $85.5 million in 2024, then soared by 341.06% to $377.1 million in 2025, then slumped by 94.67% to $20.1 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $20.1 million (Q2 2026), $42.6 million (Q1 2026), and $377.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.09 Mn |
| Mar 31, 2026 | 42.61 Mn |
| Dec 31, 2025 | 377.11 Mn |
| Sep 30, 2025 | 125.31 Mn |
| Jun 30, 2025 | 81.59 Mn |
| Mar 31, 2025 | 113.49 Mn |
| Dec 31, 2024 | 85.50 Mn |
| Sep 30, 2024 | 85.84 Mn |
| Jun 30, 2024 | 56.46 Mn |
| Mar 31, 2024 | 82.49 Mn |
| Dec 31, 2023 | 63.58 Mn |
| Sep 30, 2023 | 51.40 Mn |
| Jun 30, 2023 | 136.94 Mn |
| Mar 31, 2023 | 103.61 Mn |
| Dec 31, 2022 | 90.63 Mn |
| Sep 30, 2022 | 81.07 Mn |
| Jun 30, 2022 | 49.15 Mn |
| Mar 31, 2022 | 60.78 Mn |
| Dec 31, 2021 | 53.93 Mn |
| Sep 30, 2021 | 65.58 Mn |